Clavis Pharma raises $27 million
This article was originally published in Scrip
Executive Summary
Oslo-listed Clavis Pharma has closed a private placement to raise NOK163 million ($27 million). The money will give it greater flexibility in negotiating out-licensing deals, envisaged in 2013, and to consider new cancer product opportunities, it said. The firm has two advanced-stage oncology products, elacytarabine and CP-4126, for which key data is expected over the next year or so.